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Objective: The detection rate of sentinel lymph nodes in patients with non–small cell
lung cancer using isosulfan blue dye is too low for clinical use. Although exposure
to radioactivity is reportedly minimal, special procedures are nonetheless required
when a radioactive isotope is used as a tracer. Therefore, to eliminate the need for
a radioactive tracer and to obtain a better detection rate than is obtained with
isosulfan blue dye, we have developed a novel method that employs magnetite as the
tracer. The aim of the present study was to test the feasibility of this technique.
Methods: The tracer employed was ferumoxides, a colloidal superparamagnetic iron
oxide of nonstoichiometric magnetite. Thirty-eight non–small cell lung cancer
patients participated in the study; each received 5 mL of ferumoxides, injected
around the tumor intraoperatively. Fifteen minutes after injection, lung resection and
lymph node dissection were carried out. The magnetic force within the lymph nodes
was measured using a highly sensitive handheld magnetometer ex vivo. All lymph
nodes were also subjected to conventional histological analysis.
Results: The rate of detection of sentinel lymph nodes was 81.6% (31/38). The
accuracy, sensitivity, and false-negative rates were 96.8% (30/31), 85.7% (6/7), and
14.3% (1/7), respectively.
Conclusion: Intraoperative sentinel lymph node mapping using ferumoxides and a
highly sensitive magnetometer is a safe, accurate, and sensitive way to detect
sentinel lymph nodes in non–small cell lung cancer patients.
Mediastinal lymph node dissection (MLND) is an effectivetherapeutic procedure when carried out in patients with met-astatic non–small cell lung cancer (NSCLC); moreover, thestatus of lymph node metastasis is an important prognosticindicator.1,2 On the other hand, MLND is not therapeutic andmay even be harmful for patients without lymph node metas-
tasis.
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The sentinel lymph node (SLN) concept is that lymphatic
flux from a primary tumor initially flows into an SLN. If this
concept is correct, then when metastasis is not found in an
SLN, it most likely will not be present in more distal lymph
nodes. Although the benefit of SLN mapping and biopsy
remains controversial, it has gained acceptance in recent
years as a way to avoid the complications of lymph node
dissection and has become a common procedure in breast
cancer and melanoma.3,4 On the other hand, the SLN con-
cept is still under investigation and not yet approved for
NSCLC.
Thus far, there have been only 5 reports from 4 groups,
including this paper, on the use of SLN mapping with
NSCLC.5-8 Two tracers, isotope and isosulfan blue dye,
have been used to locate SLNs intraoperatively.5-8 Little and
colleagues8 injected peritumoral regions with isosulfan blue
dye; Liptay and coworkers6,7 intraoperatively injected tech-
netium 99m sulfur colloid directly into lung tumors and
detected SLNs with a gamma probe; and Nomori’s group5
injected technetium 99m tin colloid into peritumoral regions
preoperatively using a computed tomography-guided tech-
nique, and then detected SLNs intraoperatively using a
gamma probe. These 3 groups demonstrated the feasibility
of their methods and the utility of the SLN concept in
NSCLC. Unfortunately, none of these techniques is prob-
lem-free: precautions must be taken to minimize exposure
to radioisotopes; it is difficult to recognize isosulfan blue
dye in thoracic lymph nodes because of anthoracosis; and in
Japan the use of radioisotopes is strictly prohibited except in
designated areas.
To solve these problems, we developed a new method for
detecting SLN using magnetic force. As a tracer, we applied
colloidal ferumoxides, which is a superparamagnetic iron
oxide of nonstoichiometric magnetite that has already been
approved for clinical use in numerous countries as a contrast
material for magnetic resonance imaging. We also devel-
oped a highly sensitive, handheld magnetometer to detect
the magnetic force of the ferumoxides within SLNs. Using
this technique, we were able to detect SLNs safely in the
patients with NSCLC, without the use of radioisotopes or
dye.
Patients and Methods
Tracer
Ferumoxides, a colloidal superparamagnetic iron oxide of nons-
toichiometric magnetite (Feridex; Eiken Chemistry Co, Tokyo,
Japan), was used as the tracer. Particle diameters ranged from 70
to 140 nm; the average size was about 100 nm.
Patients
Thirty-eight consecutive patients with NSCLC were enrolled in the
study between May 2001 and February 2002 after obtaining
signed, informed consent. After the preoperative evaluation, the
patients were taken to an operating room, and the standard prep-
arations were made for a thoracotomy and lung resection. None of
the patients received preoperative chemotherapy or radiotherapy.
Intraoperative Technique
After thoracotomy, ferumoxides was injected around the tumor; a
total dosage of 5.0 mL was administered in four 1.25-mL doses in
a 4-quadrant region. To avoid surgical destruction of the lymphatic
system of the pleura and along the bronchi and vessels, we waited
for 15 minutes after injection before proceeding. To promote
migration of ferumoxides throughout the lymphatic vessels, ven-
tilation was continued during the waiting period. The time from the
injection of the ferumoxides to the harvest of the individual lymph
nodes was recorded. The lymph node station was based on the
classification by Naruke and colleagues.9 After the operation, the
magnetic force in the lymph nodes was measured ex vivo using a
highly sensitive, handheld magnetometer developed in our institute
(Figure 1). This device enabled us to measure magnetic forces of
up to 3 T in the operating room (patent pending). Magnetic force
values were expressed in terms of millivolts because the absolute
magnetic force varied depending on the distance between the
magnetometer and the samples. Ferumoxides migration was con-
sidered successful if a specific nodal station counts was greater
than 5.0 mV; the background signal was 3.0 mV. If a lymph node
station was found to have the highest or second highest signal and
ex vivo measurements were greater than 5.0 mV, that station was
classified to be an SLN.
Pathologic Evaluation
All dissected lymph nodes were sectioned and conventionally
examined using hematoxylin and eosin staining.
Figure 1. The handheld magnetometer.
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Results
The patient characteristics are summarized in Table 1.
Pathological analysis revealed that 31 of the 38 patients had
no nodal metastasis. No complications related to the injec-
tion with ferumoxides were detected, and successful migra-
tion was detected in 31 of the 38 patients (detection rate
81.6%). The mean ferumoxides migration time was 85.7
minutes. To confirm migration to the lymph nodes, we
histologically examined a magnetic force-positive lymph
node and found that ferumoxides was present mainly in the
macrophages (Figure 2).
Table 2 summarizes the results of SLN identification.
Histological analysis revealed lymph node metastases in 7
of the 31 patients (24 of the 31 patients were N0); metas-
tases were detected in 6 of the 31 patients with ferumoxides-
positive lymph nodes. Of those 6 patients, 5 showed
metastases in both ferumoxides-positive and ferumoxides-
negative nodes; in these cases, it was unclear which node
was affected first or whether the ferumoxides-positive node
had served as an SLN. However, it was notable that the
remaining 1 patient showed metastasis exclusively in the
ferumoxides-positive node, suggesting that indeed the feru-
moxides-positive node was the SLN and that the SLN
concept is applicable to NSCLC. Thus, we were able to
accurately identify the SLN in 30 of 31 patients (96.8%),
and we inaccurately identified the SLN in only 1 patient.
The sensitivity and false-negative rates were 85.7% and
14.3%, respectively.
The locations of the SLNs detected by our method are
shown in Table 3. In 8 of the 31 patients (25.8%), the SLN
was located in the N2 station alone, which suggests that the
first station of lymphatic drainage was the mediastinal
lymph nodes. These were 5 subcarinal level 7 nodes from 4
lower lobe tumors and 1 right upper lobe tumor; 2 paratracheal
level 4 nodes from right lower lobe and left upper lobe tumors;
1 upper paratracheal level 2 node from a right middle lobe
tumor; and 1 pulmonary ligament level 9 node from a right
lower lobe tumor. In 1 of those 8 patients, SLNs were located
in both levels 4 and 9 from a right lower lobe tumor.
Discussion
In the present study, we used a new ex vivo technique in
which ferumoxides was detected with a highly sensitive,
handheld magnetometer in patients with NSCLC. The de-
tection, accuracy, sensitivity, and false-negative rates ob-
tained with this method were 81.6%, 96.8%, 85.7%, and
14.3%, respectively. We therefore believe this method to be
a safe and effective way to detect SLNs in NSCLC patients.
The primary utility of SLN mapping and biopsy is to
avoid nontherapeutic lymph node dissection and the com-
plications it causes. Indeed, SLN mapping and biopsy were
developed as techniques for staging the lymphatic basin
without the potential morbidity of lymphedema and nerve
injury in cases of melanoma3 or lymphedema of the arm in
cases of breast cancer.4 Lung resection for NSCLC with
MLND leads to greater production of postoperative exudate
than lung resection without MLND, although the morbidity
of MLND is not excessive,10 and the procedure is therapeu-
tic.1 Liptay and colleagues6,7 argued that the primary func-
tion of SLN mapping and biopsy is to direct pathologic
examination to specific SLNs, after which more sensitive
techniques can be employed on a limited amount of tissue to
detect occult micrometastatic disease.6,7 Nomori and his
colleagues5 emphasized the advantage of avoiding non-
therapeutic lymph node dissection, especially in segmentec-
tomy for the early-stage NSCLC. We believe that we can
also apply SLN mapping and biopsy to video-assisted tho-
racoscopic surgery (VATS) for NSCLC. Although lymph
node dissection with VATS lobectomy is technically feasi-
ble, with remnants of only 2% to 3% of lymph node and
other tissues,11 it remains technically difficult to dissect
mediastinal lymph nodes completely, particularly level 4 in
left lung cancer. If we could apply SLN mapping and biopsy
to VATS lobectomy for NSCLC, we could avoid nonthera-
peutic and technically difficult MLND.
Although radioactive isotopes or isosulfan blue dye are
currently used to locate SLNs in breast cancer,12,13 neither
of these techniques is problem-free. Precautions are needed
to minimize exposure to radioisotopes, and anaphylactic
reactions to isosulfan blue have been reported.14 Further-
more, it is difficult to recognize isosulfan blue dye in
thoracic lymph nodes because of the anthoracosis. In fact,
the detection rate of SLNs in patients with NSCLC using
isosulfan blue dye is quite low.8
TABLE 1. Patient characteristics
Patients 38 Tumor location
Age (y) RUL 8
Mean 65.4  9.7 RML 3
Range 42–79 RLL 8
Sex Female 14,
Male 24
LUL 11
LLL 8
Pathological nodal
status
N0 31 Tumor size (cm)
N1 4 Mean 2.9  1.7
N2 3 Range 0.8–8.0
Pathological stage Histological type
Stage IA 16 ad 27
Stage IB 12 sq 9
Stage IIA 1 La 2
Stage IIB 4 Operation
Stage IIIA 2 Lobectomy 33
Stage IIIB 2 Sleeve
lobectomy
2
Stage IV 1 Pneumonectomy 3
RUL, Right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL,
left upper lobe; LLL, left lower lobe; ad, adenocarcinoma; sq, squamous cell
carcinoma; La, large cell carcinoma.
Nakagawa et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 2 565
G
TS
In the breast cancer field, numerous investigators have
reported that when using a radioactive tracer, the radiation
risk to surgeons, pathologists, and other medical staff to
radiation is minimal,15-17 and the risk to patients is no
greater than with numerous other medical procedures.16 The
radiation levels in the waste are also low.15 Nevertheless,
radioactive materials always need to be handled with care to
avoid secondary contamination; for example, Waddington
and coworkers16 reported that surgical swabs can contain up
to 22% of the administered activity. Awareness of and
adherence to radiation safety regulations are strongly rec-
ommended to minimize exposure and to safely apply the
technique.17 Thus, although the radio-guided method is
quite a safe procedure, special procedures must be em-
ployed. Furthermore, the use of radioisotopes in Japan is
Figure 2. Sentinel lymph node detected with magnetic force. Representative hematoxylin and eosin-stained
micrograph (40) confirming ferumoxides migration to the lymph node detected with handheld magnetometer.
Ferumoxides was mainly observed in macrophages within the harvested lymph nodes.
TABLE 2. Sentinel lymph node identification
Identification n Migration time
SLN identified (successful
migration of FE)
31 of 38 (81.6%) 85.7 min (22–172)
Number of metastases 7 of 31 (22.6%)
Metastases in FE ()
nodes
6 of 31 (19.4%)
Metastases in FE ()
nodes (inaccurately
identified SLN)
1 of 31 (3.2%)
Accurately identified SLN 30 of 31 (96.8%)
Sensitivity (metastases in
FE () nodes/number of
metastases)
6 of 7 (85.7%)
False-negative (metastases
in FE () nodes/number
of metastases)
1 of 7 (14.3%)
SLN not identified
No migration of FE 7 of 38 (18.4%)
Lymph node metastasis was evaluated with H&E staining. FE, Ferumoxides.
TABLE 3. Sentinel lymph node location
Tumor
location
Number of
cases
N1
alone
N2
alone
N1 and
N2
RUL 6 2 1 3
RML 3 1 1 1
RLL 6 2 3 1
LUL 9 8 1 0
LLL 7 2 2 3
Total 31 15 8 8
RUL, Right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL,
left upper lobe; LLL, left lower lobe.
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strictly limited to designated areas. By contrast, no such
precautions are required when handling magnetite. We
therefore believe that magnetic-guided SLN mapping is
more practical and effective than radio-guided mapping.
The SLN detection rate of 81.6% obtained in our study
compares favorably with the 82% rate reported by Liptay
and colleagues6 for radio-guided mapping using technetium
99m sulfur colloid and the 87% rate reported by Nomori and
coworkers5 for radio-guided mapping using technetium
99m tin colloid. Notably, Nomori’s group also reported that
patients whose sentinel nodes could not be identified had a
significantly lower ratio of forced expiratory volume in 1
second to forced vital capacity than did patients with iden-
tifiable sentinel node.5 Destruction of the lymphatic vessels
in the alveolar septa and along the airway in chronic ob-
structive pulmonary disease may explain this phenomenon,
though full clarification of the reason for the failure to detect
SLNs in some cases awaits further investigation.
The particle diameters of technetium 99m sulfur colloid,
ferumoxides, and technetium 99m tin colloid are approxi-
mately 40 nm, 100 nm, and 1000 nm, respectively. More
time was required for ferumoxides to migrate to a sentinel
node station (85.7 minutes) than for technetium 99m sulfur
colloid (10 to 15 minutes).6 By contrast, because of its
comparatively large size, the migration time for technetium
99m tin colloid was at least 6 hours, which meant that it had
to be injected preoperatively.5 On the other hand, ferumox-
ides can be injected intraoperatively, which is advantageous
as it enables us to avoid the risks of pneumothorax, bleed-
ing, and tumor seeding. Moreover, it eliminates the need of
another preoperative procedure. A disadvantage of the
smaller particles is the risk of false-positives, as small
particles sometimes pass through the true SLN and flow up
the chain of nodes. In fact, we detected magnetic force in
non-SLNs but were able to distinguish the SLN from other
nodes based on the intensity of the signal.
In the present study, the SLN was mediastinal (N2) in 8
of 31 patients (25.8%), which is consistent with previous
reports.5-7 The prognosis of patients with skip N2 metastasis
is reportedly better than patients with other N2 metastases
and similar to those with N1 metastasis.18 The incidence of
skip metastasis in mediastinal lymph nodes is between 20%
and 40% in NSCLC.19-21 Perhaps SLN investigation will
shed light on the mechanism of skip metastasis in NSCLC.
In summary, we have developed a new ex vivo method
of SLN mapping using ferumoxides with a highly sensitive
handheld magnetometer. This method appears to be as ac-
curate and sensitive as SLN mapping using technetium;
however, only a limited number of patients were investi-
gated. Further investigation will thus be required to confirm
the feasibility and safety of this approach. In addition, our
magnetometer is not yet suitable for in vivo SLN mapping;
development of such an instrument is planned, however.
We thank Ms Mitsuko Sato and Jun Kodama for secretarial
support.
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